Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-777 Monotherapy and Combination with AT-527 in Healthy and HCV-Infected Subjects
NCT04309734Phase 2Withdrawn
- Sponsor
- Atea Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AT-777 in hepatitis C (HCV), sponsored by Atea Pharmaceuticals. Planned start Oct 2021; status: withdrawn.
02
Drugs
AT-777
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04309734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309734.